COMPANY:

DermTech

"DermTech, Inc...announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California...The first research abstract, 'Non-invasive gene expression analyses to rule out melanoma in patients with Fitzpatrick skin types IV-VI” will be presented'..."

"DermTech, Inc...today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting...Using follow-up information and biopsy results from a large registry database that also served as the basis for the Company’s recently completed Trust 2 Study, this study compared the DMT’s performance in patients with Fitzpatrick skin phototypes I-III (n=4,152) to its performance in patients with skin phototypes IV-VI (n=130)....The negative predictive value (NPV) for both groups (I-III and IV-VI) was greater than 99%, and the 95% confidence interval for the difference in NPV between the groups indicated that there was no significant difference between the skin phototype groups."

"DermTech, Inc...announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024...Multiple studies, including the Company’s recently completed Trust 2 Study, demonstrated the DMT’s negative predictive value (NPV) to be 99% or higher. A high NPV for a rule-out test provides assurance to clinicians and patients that a suspicious pigmented lesion which tests negative is unlikely to be a melanoma."

"DermTech, Inc...today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting...The Trust 2 Study, initiated in 2021, enrolled over 20,000 patients tested with the DMT in a real-world clinical setting....The Trust 2 Study results demonstrated an NPV of 99.7% for the foundational gene expression assay component of the DMT. The NPV of 99.7% was observed (rather than calculated from an assumed prevalence), and was associated with a narrow 95% confidence interval of 99.5% to 99.9%."

"DermTech, Inc...announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT)."

"DermTech, Inc...announced a favorable coverage policy with a Blues plan in Michigan. The favorable coverage policy, which is in addition to a contract that became effective in August 2022, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 4.5 million members of this plan. The Pigmented Lesion Assay (PLA), the foundational assay of the DMT, is an innovative, non-invasive way to rule out melanoma with a 99 percent negative predictive value (NPV)....DermTech’s total covered lives in the U.S. are approximately 133 million, which includes 68 million for Medicare/Medicare Advantage and 65 million for commercial and governmental payers."

"DermTech, Inc...announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York. The Pigmented Lesion Assay (PLA), the foundational assay of the DMT, is an innovative, non-invasive way to rule out melanoma with a 99 percent negative predictive value (NPV)....DermTech’s total covered lives in the U.S. are approximately 133 million, which includes 68 million for Medicare/Medicare Advantage and 65 million for commercial and governmental payers."

"DermTech, Inc...announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for the DermTech Melanoma Test (DMT), and changed its rating from ‘Inconclusive’ to ‘Somewhat Favorable’. ECRI is an independent, nonprofit organization focused on healthcare technology evaluation and safety to improve quality, reduce cost and achieve better outcomes across all healthcare settings."

"DermTech, Inc...announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan."

"DermTech, Inc...announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT uses non-invasive Smart Stickers™ to test for select genomic markers associated with melanoma, one of the deadliest forms of skin cancer. With a negative predictive value of over 99 percent, the test rules out melanoma with high probability."

"DermTech, Inc...announced agreements with a Blues plan in South Carolina and the United Mine Workers of America Health and Retirement Funds ('UMWA Funds'). The contracts, which are both effective April 1, 2023, enhance access to the foundational assay of the DermTech Melanoma Test ('DMT') for the approximately 1.7 million members of the Blues plan in South Carolina and the 90,000 beneficiaries of the UMWA Funds. The UMWA Funds is a group of multi-employer plans that provide health and pension benefits to retired coal miners and their eligible dependents. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value ('NPV')."

"DermTech, Inc...announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 400,000 members of this plan....DermTech’s total covered lives in the U.S. are approximately 126 million, which includes 68 million for Medicare/Medicare Advantage and 58 million for commercial and governmental payers."

"DermTech, Inc...announced an agreement with a Blues plan in North Carolina. The contract, which is in addition to a favorable coverage policy that became effective March 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the more than 3.8 million members of this plan."

"DermTech, Inc...announced that it is participating in the 2023 American Academy of Dermatology (AAD) Annual Meeting, which will take place on March 17-21 in New Orleans...DermTech will present four new posters focused on topics including the efforts in development of a basal cell carcinoma diagnostic gene signature and evaluation of the DermTech Melanoma Test (DMT) in higher Fitzpatrick Skin Types."

"DermTech, Inc...announced an agreement with a Blues plan in Arizona. The agreement makes the foundational assay of the DermTech Melanoma Test (DMT) available to the approximately 1.9 million members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV)."

"DermTech, Inc...announced that U.S. General Services Administration has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA)."

"DermTech, Inc...announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies resulted from an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the Medicare coverage policy of the Company’s foundational assay included in the DermTech Melanoma Test (DMT)."

"DermTech, Inc...announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world."

"DermTech, Inc...announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (BCBS NC), Blue Cross Blue Shield of South Carolina (BCBS SC), Blue Cross Blue Shield of Louisiana (BCBS LA) and Blue Cross Blue Shield of Kansas City (BCBS KC). These coverage policies were announced pursuant to an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the policy issued by Medicare for coverage of the Company’s foundational assay for the DermTech Melanoma Test (DMT)."

"DermTech, Inc...announced...an agreement with Sonora Quest Laboratories (Sonora Quest)...to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network of healthcare providers...The DermTech Melanoma Test uses a non-invasive Smart Sticker™ to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma."

"DermTech, Inc...announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego...The presentation, titled 'Translational Research to Revolutionize Dermatologic Care,' emphasized the Company’s proprietary Smart Sticker™ and platform technology, highlighting its capabilities, specializations and advantages."

"DermTech, Inc...announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans (AHIP) 2022. The meeting is being held from June 21-23, 2022 in Las Vegas, Nev...Title - Transforming the Future of Dermatology Through Genomic Innovation..."

"DermTech, Inc...announced today that it is sponsoring The Sun Bus, a community service provided by the Colorado Melanoma Foundation in partnership with Epiphany Dermatology, to bring free skin cancer screenings and public education to communities across the U.S. The Sun Bus is a mobile screening station and sun safety classroom that is expected to serve more than 50 locations nationwide in 2022."

"DermTech, Inc...announced today that SKIN: The Journal of Cutaneous Medicine has published its original research study...By incorporating the Pigmented Lesion Assay ('PLA') into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma, the study highlights the potential reduction in cost for commercial health insurance plans, in addition to a higher quality of care for patients and improved health outcomes."

"BioIQ, Inc...nd DermTech, Inc...announced an agreement to bring increased patient access to precision genomics. The DermTech Melanoma Test is now included in BioIQ's lineup of testing options for employee and member health programs. The program will be available in Florida initially with planned expansion to other states."

"DermTech, Inc...announced today the expansion and branding of its translational medicine service offering, DermTech Stratum™, which utilizes DermTech’s non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development...The DermTech Stratum service offering is appropriate for indications where skin is the target or a surrogate target organ and are being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research studies."

"DermTech, Inc...announced today an agreement to make the DermTech Melanoma Test available through DermatologistOnCall’s telemedicine platform. The millions of patients served through DermatologistOnCall will now have increased access to DermTech’s non-invasive, precision genomics tests for melanoma, the leading cause of skin cancer deaths...The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via the DermTech Smart Sticker™. A patient sample can be collected at home under virtual supervision by a trained DermatologistOnCall clinician. The sample is sent to the DermTech Gene Lab where it is tested for genomic markers linked to melanoma."